Macrogenics (MGNX) Tops Q2 EPS, Revenues Miss
Tweet
Share
E-mailGet Alerts MGNX Hot Sheet
Join SI Premium – FREE
Macrogenics (NASDAQ: MGNX) reported Q2 EPS of $0.92, $1.44 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $13.1 million versus the consensus estimate of $29.19 million.
For earnings history and earnings-related data on Macrogenics (MGNX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Macrogenics (MGNX) Misses Q2 EPS by 102c
- Lument Finance Trust (LFT) Misses Q2 EPS by 17c
- Eledon Pharmaceuticals, Inc. (ELDN) Misses Q2 EPS by 12c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
